Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Grand View Research | PRODUCT CODE: 1941553

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1941553

Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment (Surgery, Radiation Therapy, Chemotherapy), By End Use (Hospitals, Ambulatory Surgery Centers), By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Glioblastoma Multiforme Treatment Market Summary

The global glioblastoma multiforme treatment market size was estimated at USD 4.04 billion in 2025 and is projected to reach USD 7.87 billion by 2033, growing at a CAGR of 8.69% from 2026 to 2033. The rising prevalence of Glioblastoma Multiforme (GBM) and its significant clinical burden are critical drivers in the GBM treatment industry.

The expanding evidence base has reinforced temozolomide's (TMZ) role as a cornerstone in glioblastoma multiforme (GBM) treatment. Several recent real-world studies and meta-analyses have shown that continuing TMZ therapy beyond the standard six cycles may provide additional survival benefits, particularly in patients with favorable molecular features such as MGMT promoter methylation or low Ki-67 expression. A meta-analysis published in Neuro-Oncology Advances in July 2023 reviewed outcomes from 2,578 patients across 16 nonrandomized studies and 5 randomized controlled trials. The analysis found that extended therapy was linked to a 28% reduction in disease progression and a 29% decrease in mortality risk, though most of these benefits were observed in retrospective cohorts. These findings highlight the need for further randomized investigations to establish the definitive value of prolonged adjuvant use. In addition, ongoing trials are evaluating TMZ in combination with immunotherapies and tumor-treating fields, supported by its tolerability and consistent clinical performance.

Cost-effectiveness and broad availability have also contributed to the widespread uptake of TMZ worldwide. The introduction of generic formulations has reduced treatment expenses, improving access without compromising therapeutic outcomes. Its favorable safety profile and established efficacy make it a preferred choice across diverse healthcare systems. A Phase IIa trial, published in March 2023 in the Journal of Clinical Oncology, assessed the SurVaxM vaccine alongside adjuvant TMZ in newly diagnosed GBM patients. Results demonstrated a median progression-free survival of 11.4 months and an overall survival of 25.9 months, with robust immune responses and no severe vaccine-related side effects, underscoring the potential of combination approaches. As emerging therapies evolve, many continue to build on TMZ as a foundation, reinforcing its critical role in the standard management of GBM.

The global uptake of tumor treating fields (TTF) continues to accelerate, supported by broader access and favorable reimbursement policies. Many healthcare systems have included TTF among reimbursable treatment options, reducing financial hurdles for patients who qualify. By late 2024, Novocure reported more than 4,000 patients worldwide actively using its Optune Gio TTF system, with strong adoption in regions such as the United States, Germany, France, and Japan. This rising user base reflects growing physician confidence and patient acceptance of the therapy across both advanced and emerging healthcare settings. The positive outcomes are also driving innovation, with ongoing efforts focused on technological upgrades and expanding its use in other tumor types. Collectively, these developments are positioning TTF as an integral element in the evolving management of glioblastoma multiforme.

The five-year survival data shows a marked difference between treatment approaches, with radiation therapy (RT) alone resulting in a 16.2% survival rate compared to 83.8% when combined with temozolomide (TMZ). This demonstrates the significant clinical advantage of multimodal therapy, particularly TMZ's role in enhancing outcomes for GBM patients. Such findings validate the continued reliance on TMZ as the backbone of GBM therapy and reinforce the demand for chemotherapy drugs in combination protocols. The evidence also supports healthcare providers' preference for integrated treatment approaches, strengthening the adoption of combination therapies in clinical practice.

From a market perspective, this survival benefit will continue to drive investment in combination regimens and fuel demand for supportive therapeutics like TMZ. Pharmaceutical companies are expected to leverage these outcomes by developing next-generation therapies that complement or enhance TMZ's effects, including immunotherapies and targeted agents. The higher survival outcomes with RT+TMZ will influence treatment guidelines, leading to broader reimbursement coverage and increased uptake across hospitals and cancer centers. This shift will not only sustain the dominance of TMZ in the GBM treatment market but also create opportunities for novel adjunctive therapies positioned alongside it.

Global Glioblastoma Multiforme Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global glioblastoma multiforme treatment market report based on treatment, end use, and region:

  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Surgery
  • Radiation Therapy
  • Chemotherapy
    • Temozolomide
    • Lomustine
    • Carmustine Wafers
    • Other
  • Targeted Therapy (Bevacizumab)
  • Tumor Treating Field (TTF) Therapy
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Clinics / Outpatient Centers
  • Ambulatory Surgical Centers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-4-68039-527-3

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Glioblastoma Multiforme Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Glioblastoma Multiforme Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2025 & 2033
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 4.4. Surgery
    • 4.4.1. Surgery Market, 2021 - 2033 (USD Million)
  • 4.5. Radiation Therapy
    • 4.5.1. Radiation Therapy Market, 2021 - 2033 (USD Million)
  • 4.6. Chemotherapy
    • 4.6.1. Chemotherapy Market, 2021 - 2033 (USD Million)
    • 4.6.2. Temozolomide
      • 4.6.2.1. Temozolomide Market, 2021 - 2033 (USD Million)
    • 4.6.3. Lomustine
      • 4.6.3.1. Lomustine Market, 2021 - 2033 (USD Million)
    • 4.6.4. Carmustine Wafers
      • 4.6.4.1. Carmustine Wafers Market, 2021 - 2033 (USD Million)
    • 4.6.5. Other
      • 4.6.5.1. Other Market, 2021 - 2033 (USD Million)
  • 4.7. Targeted Therapy (Bevacizumab)
    • 4.7.1. Targeted Therapy (Bevacizumab) Market, 2021 - 2033 (USD Million)
  • 4.8. Tumor Treating Field (TTF) Therapy
    • 4.8.1. Tumor Treating Field (TTF) Therapy Market, 2021 - 2033 (USD Million)

Chapter 5. Glioblastoma Multiforme Treatment Market: End Use Business Analysis

  • 5.1. End Use Market Share, 2025 & 2033
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals Market, 2021 - 2033 (USD Million)
  • 5.5. Clinics / Outpatient Centers
    • 5.5.1. Clinics / Outpatient Centers Market, 2021 - 2033 (USD Million)
  • 5.6. Ambulatory Surgical Centers
    • 5.6.1. Ambulatory Surgical Centers Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Glioblastoma Multiforme Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Glioblastoma Multiforme Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Glioblastoma Multiforme Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Merck & Co., Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Treatment Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Amgen, Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Treatment Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. F. Hoffmann-La Roche Ltd.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Treatment Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Pfizer Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Treatment Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Teva Pharmaceutical Industries Ltd.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Treatment Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Sun Pharmaceutical Industries Ltd.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Treatment Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Arbor Pharmaceuticals, LLC
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Treatment Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Amneal Pharmaceuticals
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Treatment Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Karyopharm Therapeutics, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Treatment Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Treatment Benchmarking
      • 7.5.10.4. Strategic Initiatives
Show more
Product Code: GVR-4-68039-527-3

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global glioblastoma multiforme treatment market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 5 Global glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 6 North America glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 8 North America glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 9 U.S. glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 10 U.S. glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Canada glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 12 Canada glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 13 Mexico glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 14 Mexico glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Europe glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 17 Europe glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 18 UK glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 19 UK glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 20 Germany glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 21 Germany glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 22 France glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 23 France glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 24 Italy glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 25 Italy glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 26 Spain glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 27 Spain glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 28 Norway glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 29 Norway glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 30 Denmark glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 31 Denmark glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 32 Sweden glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 33 Sweden glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 37 Japan glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 38 Japan glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 39 China glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 40 China glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 41 India glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 42 India glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Australia glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 44 Australia glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 45 South Korea glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 46 South Korea glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 47 Thailand glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 48 Thailand glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 49 Latin America glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 51 Latin America glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 52 Brazil glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 53 Brazil glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 54 Argentina glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 55 Argentina glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Glioblastoma multiforme treatment market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 59 South Africa glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 60 South Africa glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 63 UAE glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 64 UAE glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)
  • Table 65 Kuwait glioblastoma multiforme treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 66 Kuwait glioblastoma multiforme treatment market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Glioblastoma multiforme treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Glioblastoma multiforme treatment market dynamics
  • Fig. 11 Glioblastoma multiforme treatment market: Porter's five forces analysis
  • Fig. 12 Glioblastoma multiforme treatment market: PESTLE analysis
  • Fig. 13 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 14 Surgery market, 2021 - 2033 (USD Million)
  • Fig. 15 Radiation therapy market, 2021 - 2033 (USD Million)
  • Fig. 16 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 17 Temozolomide market, 2021 - 2033 (USD Million)
  • Fig. 18 Lomustine market, 2021 - 2033 (USD Million)
  • Fig. 19 Carmustine Wafers market, 2021 - 2033 (USD Million)
  • Fig. 20 Other market, 2021 - 2033 (USD Million)
  • Fig. 21 Targeted therapy (Bevacizumab) market, 2021 - 2033 (USD Million)
  • Fig. 22 Tumor treating field (TTF) Therapy market, 2021 - 2033 (USD Million)
  • Fig. 23 End use market, 2021 - 2033 (USD Million)
  • Fig. 24 Hospitals market, 2021 - 2033 (USD Million)
  • Fig. 25 Clinics / outpatient centers market, 2021 - 2033 (USD Million)
  • Fig. 26 Ambulatory surgical centers market, 2021 - 2033 (USD Million)
  • Fig. 27 Others market, 2021 - 2033 (USD Million)
  • Fig. 28 Glioblastoma multiforme treatment market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 North America glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. country dynamics
  • Fig. 32 U.S. glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 33 Canada country dynamics
  • Fig. 34 Canada glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 35 Mexico country dynamics
  • Fig. 36 Mexico glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 37 Europe glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 38 UK country dynamics
  • Fig. 39 UK glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 40 Germany country dynamics
  • Fig. 41 Germany glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 42 France country dynamics
  • Fig. 43 France glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 44 Italy country dynamics
  • Fig. 45 Italy glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 46 Spain country dynamics
  • Fig. 47 Spain glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 48 Norway country dynamics
  • Fig. 49 Norway glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 50 Sweden country dynamics
  • Fig. 51 Sweden glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 52 Denmark country dynamics
  • Fig. 53 Denmark glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 54 Asia Pacific glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 55 Japan country dynamics
  • Fig. 56 Japan glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 57 China country dynamics
  • Fig. 58 China glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 59 India country dynamics
  • Fig. 60 India glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 61 Australia country dynamics
  • Fig. 62 Australia glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 63 South Korea country dynamics
  • Fig. 64 South Korea glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 65 Thailand country dynamics
  • Fig. 66 Thailand glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 67 Latin America glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 68 Brazil country dynamics
  • Fig. 69 Brazil glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 70 Argentina country dynamics
  • Fig. 71 Argentina glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 72 MEA glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 73 South Africa country dynamics
  • Fig. 74 South Africa glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 75 Saudi Arabia country dynamics
  • Fig. 76 Saudi Arabia glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 77 UAE country dynamics
  • Fig. 78 UAE glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 79 Kuwait country dynamics
  • Fig. 80 Kuwait glioblastoma multiforme treatment market, 2021 - 2033 (USD Million)
  • Fig. 81 Company categorization
  • Fig. 82 Company market position analysis
  • Fig. 83 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!